Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis | oneAMYLOIDOSISvoice
Scientific Articles

Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis

key information

source: Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry

year: 2015

authors: Niemietz C, Chandhok G, Schmidt H


The liver has become an increasingly interesting target for oligonucleotide therapy. Mutations of the gene encoding transthyretin (TTR), expressed in vast amounts by the liver, result in a complex degenerative disease, termed familial amyloid polyneuropathy (FAP). Misfolded variants of TTR are linked to the establishment of extracellular protein deposition in various tissues, including the heart and the peripheral nervous system. Recent progress in the chemistry and formulation of antisense (ASO) and small interfering RNA (siRNA) designed for a knockdown of TTR mRNA in the liver has allowed to address the issue of gene-specific molecular therapy in a clinical setting of FAP. The two therapeutic oligonucleotides bind to RNA in a sequence specific manner but exploit different mechanisms. Here we describe major developments that have led to the advent of therapeutic oligonucleotides for treatment of TTR-related disease.

organization: Universitätsklinikum Münster, Germany

DOI: 10.3390/molecules201017944

read more full text source


The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.